Summer Sale! Save 25%
Free Express Shipping
Sale Ends: 06/27
Uses
Side effects
Interactions
Precautions
RISPERDAL® is an atypical antipsychotic agent indicated for:
- Treatment of schizophrenia in adults and adolescents aged 13-17 years
- Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults, and alone in children and adolescents aged 10-17 years
• Treatment of irritability associated with autistic disorder in children and adolescents aged 5-16 years
- The most common adverse reactions in clinical trials (≥10%) were somnolence, appetite increased, fatigue, rhinitis, upper respiratory tract infection, vomiting, coughing, urinary incontinence, saliva increased, constipation, fever, Parkinsonism, dystonia, abdominal pain, anxiety, nausea, dizziness, dry mouth, tremor, rash, akathisia, and dyspepsia.
- The most common adverse reactions that were associated with discontinuation from clinical trials were somnolence, nausea, abdominal pain, dizziness, vomiting, agitation, and akathisia.
- Due to CNS effects, use caution when administering with other centrallyacting drugs. Avoid alcohol.
- Due to hypotensive effects, hypotensive effects of other drugs with this potential may be enhanced.
- Effects of levodopa and dopamine agonists may be antagonized.
- Cimetidine and ranitidine increase the bioavailability of risperidone.
- Clozapine may decrease clearance of risperidone.
- Fluoxetine and paroxetine increase plasma concentrations of risperidone.
- Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone.
- Cerebrovascular events, including stroke, in elderly patients with dementiarelated psychosis. RISPERDAL® is not approved for use in patients with dementia-related psychosis
- Neuroleptic Malignant Syndrome
- Tardive dyskinesia
- Hyperglycemia and diabetes mellitus
- Hyperprolactinemia
- Orthostatic hypotension
- Leukopenia, Neutropenia, and Agranulocytosis: has been reported with antipsychotics, including RISPERDAL®. Patients with a history of a clinically significant low white blood cell count (WBC) or a druginduced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of RISPERDAL® should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.
- Potential for cognitive and motor impairment
- Seizures
- Dysphagia
- Priapism
- Disruption of body temperature regulation
- Antiemetic Effect
- Suicide
- Increased sensitivity in patients with Parkinson’s disease or those with dementia with Lewy bodies
- Diseases or conditions that could affect metabolism or hemodynamic responses
